Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients
with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block
tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them.
Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.